Amicus Therapeutics to Highlight Innovations at Investor Events
This September, Amicus Therapeutics (Nasdaq: FOLD), a leading global biotechnology company, is gearing up to take the spotlight at several key investor conferences. The management team plans to connect with investors and share valuable insights about the company’s ongoing projects and innovative strategies in the field of rare diseases.
Upcoming Presentations
These presentations will take place at notable conferences, underscoring Amicus’ dedication to advancing healthcare solutions. The first event, the Morgan Stanley 22nd Annual Global Healthcare Conference, is scheduled for September 5th. During this conference, the team will present at 10:00 a.m. ET, offering an update on their pipeline and innovative strategies.
Key Conference Details
On September 17th, Amicus will also take part in the Cantor Global Healthcare Conference 2024. This event will provide executives with the opportunity to discuss their drug development initiatives in greater detail, with their presentation set for 1:55 p.m. ET. These conferences are excellent opportunities to gain insight into how Amicus Therapeutics is working towards breakthroughs in healthcare.
Accessing Live Webcasts
For those who cannot attend in person, Amicus Therapeutics will offer live audio webcasts for each presentation. Investors can easily tune in to these broadcasts through the investors section of the company’s corporate website. This feature allows anyone interested in the company’s future direction and innovations to stay informed.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is committed to developing high-quality medicines aimed at treating rare diseases. Their unwavering patient-focused strategy centers on delivering groundbreaking treatments that meet significant medical needs. With a promising pipeline, Amicus Therapeutics is determined to lead in this field, crafting solutions that enhance the lives of patients.
Commitment to Innovation
The company’s strategy combines cutting-edge research, thorough clinical trials, and meaningful patient engagement to ensure their novel therapies are both effective and accessible. Their efforts not only seek to improve the quality of life for patients but also aim to establish Amicus as a pioneering entity in the biotechnology sector.
Contact Information
Amicus Therapeutics invites open communication with investors and the media. For inquiries related to investor relations, individuals can contact Andrew Faughnan, the Vice President of Investor Relations, via email at afaughnan@amicusrx.com or by phone at (609) 662-3809.
For media inquiries, Diana Moore, the Head of Global Corporate Affairs and Communications, can be reached at dmoore@amicusrx.com or (609) 662-5079. This accessibility reflects their commitment to transparency and ongoing dialogue within the investment community.
Frequently Asked Questions
What is the purpose of Amicus Therapeutics' presentations at the conferences?
The presentations aim to provide insights into the company’s innovations and ongoing projects related to rare diseases, engaging with investors on future strategies.
How can investors access the live webcasts?
Investors can access the live audio webcasts through the investors section of the Amicus Therapeutics corporate website during the conference presentations.
Who should I contact for investor relations inquiries?
For investor relations, reach out to Andrew Faughnan at afaughnan@amicusrx.com or call (609) 662-3809 for assistance.
What types of diseases does Amicus Therapeutics focus on?
Amicus Therapeutics specifically targets rare diseases with high unmet medical needs, aiming to develop innovative therapies for affected patients.
How does Amicus Therapeutics ensure effective communication?
Amicus Therapeutics maintains open communication channels with both investors and the media, emphasizing transparency and continual engagement to build strong relationships.
